Brentuximab Vedotin-induced Tumour Lysis Syndrome in Mycosis Fungoides: A Case Report
DOI:
https://doi.org/10.2340/actadv.v104.41982Keywords:
Mycosis fungoides, Tumor lysis syndrome, Brentuximab vedotin, Cutaneous T-cell LymophomaAbstract
Abstract is missing (Short communication)
Downloads
References
Adeyinka A, Bashir K. Tumor lysis syndrome. 2022 Oct 31. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2024.
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149: 578-586.
https://doi.org/10.1111/j.1365-2141.2010.08143.x DOI: https://doi.org/10.1111/j.1365-2141.2010.08143.x
Sury K. Update on the prevention and treatment of tumor lysis syndrome. J Onco Nephrol 2019; 3: 19-30.
https://doi.org/10.1177/2399369319837212 DOI: https://doi.org/10.1177/2399369319837212
Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 2016; 95: 563-573.
https://doi.org/10.1007/s00277-015-2585-7 DOI: https://doi.org/10.1007/s00277-015-2585-7
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Brentuximab vedotin (SGN- 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-2196.
https://doi.org/10.1200/JCO.2011.38.0402 DOI: https://doi.org/10.1200/JCO.2011.38.0402
Abdelmouttalib A, Elghtaibi FZ, Sialiti S, Senouci, K. Sézary syndrome preceded by mycosis fungoides and complicated by tumor lysis syndrome and macrophage activation syndrome. Our Dermatol Online 2022; 13: 114-115.
https://doi.org/10.7241/ourd.20221.32 DOI: https://doi.org/10.7241/ourd.20221.32
Kopterides P, Lignos M, Mavrou I, Armaganidis A. Steroid- induced tumor lysis syndrome in a patient with mycosis fungoides treated for presumed pneumocystis carinii pneumonia. Am J Hematol 2005; 80: 309.
https://doi.org/10.1002/ajh.20444 DOI: https://doi.org/10.1002/ajh.20444
Brentuximab vedotin (Adcteris). European Medicines Agency (EMA) [accessed October 16, 2016]. Available from: https://www.ema.europa.eu
Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 2014; 21: 18-26.
https://doi.org/10.1053/j.ackd.2013.07.001 DOI: https://doi.org/10.1053/j.ackd.2013.07.001
Stephanos K, Picard L. Pediatric oncologic emergencies. Emerg Med Clin North Am 2018; 36: 527-535.
https://doi.org/10.1016/j.emc.2018.04.007 DOI: https://doi.org/10.1016/j.emc.2018.04.007
Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010; 51: 221-227.
https://doi.org/10.3109/10428190903456959 DOI: https://doi.org/10.3109/10428190903456959
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Berenika Olszewska, Anna Zaryczańska, Roman J. Nowicki, Małgorzata Sokołowska-Wojdyło
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
